Table 1.
Patient characteristics of the study cohorts. In this study, we developed and optimized the clinical assay using a cohort of 30 NSCLC patients. The prognostic performance of the assay was validated in the FFPE samples of a cohort with 258 NSCLC patients without ACT, and the predictive performance was validated in 207 propensity score-matched patients from the cohort of the 327 NSCLC patients. The patient characteristics of the three cohorts are summarized here:
| Assay development cohort (n=30) | Prognostic validation cohort (n=258) | Predictive validation cohort (n=207) | |
|---|---|---|---|
| Histology | |||
| ADC | 13 (43.3%) | 166 (64.3%) | 138 (66.7%) |
| SCC | 13 (43.3%) | 86 (33.3%) | 69 (33.3%) |
| Other | 4 (13.3%) | 6 (2.3%) | 0 (0.0%) |
| Stage | |||
| IA | 5 (16.7%) | 139 (53.9%) | 71 (34.3%) |
| IB | 6 (20.0%) | 80 (31.0%) | 50 (24.2%) |
| IIA | 6 (20.0%) | 23 (8.9%) | 46 (22.2%) |
| IIB | 8 (26.7%) | 16 (6.2%) | 40 (19.3%) |
| III | 4 (13.3%) | 0 (0.0%) | 0 (0.0%) |
| IV | 1 (3.3%) | 0 (0.0%) | 0 (0.0%) |
| Gender | |||
| Female | 14 (46.7%) | 129 (50.0%) | 97 (46.9%) |
| Male | 16 (53.3%) | 129 (50.0%) | 110 (53.1%) |
| Age (Year) | 68.77 | 68.08 | 63.85 |
| Follow-up time (Months) | 52.49 | 6.07 | 53.94 |
| Death | |||
| Yes | 23 (76.7%) | 193 (74.8%) | 151 (73.0%) |
| No | 7 (23.3%) | 65 (25.2%) | 56 (27.1%) |
| Adjuvant Therapy | |||
| Yes | 9 (30.0%) | 0 (0.0%) | 69 (33.3%) |
| No | 15 (50.0%) | 258 (100%) | 138 (66.7%) |